Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers Health Is Building A Hormonal Empire
05:43am, Tuesday, 06'th Jan 2026
Hims & Hers Health shares are down 30%, but I maintain a Buy rating due to compelling long-term growth levers. HIMS's core business growth is slowing, yet margin expansion, product innovation, and int
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization
01:45pm, Monday, 05'th Jan 2026
HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.
Hims & Hers: A Great Moment To Buy The Dip
10:33am, Monday, 05'th Jan 2026
Hims & Hers remains a "Buy" as recent catalysts, including renewed GLP-1 partnership talks and share buybacks, support a rebound thesis. HIMS boasts a sticky, high-margin customer base, expanding into
Critical Review: Hims & Hers Health (NYSE:HIMS) vs. Zepp Health (NYSE:ZEPP)
02:48am, Monday, 05'th Jan 2026
Hims and Hers Health (NYSE: HIMS - Get Free Report) and Zepp Health (NYSE: ZEPP - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies bas
HIMS Stock On A Losing Spree: Here's Why
08:30am, Friday, 02'nd Jan 2026
Hims & Hers Health (HIMS) stock has experienced a 7-day losing streak, resulting in total losses of 8.7% over this time frame. The company's market capitalization has plummeted by approximately $699 m
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
01:45pm, Tuesday, 30'th Dec 2025
Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.
Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses
09:15am, Tuesday, 30'th Dec 2025
Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty telehealth platform offering prescription medications, mental health support,
Top 10 Most Shorted Stocks: Lucid, MARA, Hims and More
10:30am, Monday, 29'th Dec 2025
Investors look for heavily shorted stocks either to bet on a further decline in the company's value or to profit from a potential short squeeze.
TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside
09:50am, Monday, 29'th Dec 2025
Tempus AI and Hims & Hers are riding healthcare IT growth, but diagnostics scale and consumer demand set different upside paths.
Carnegie Investment Counsel Acquires 61,560 Shares of Hims & Hers Health, Inc. $HIMS
05:15am, Saturday, 27'th Dec 2025
Carnegie Investment Counsel lifted its holdings in Hims and Hers Health, Inc. (NYSE: HIMS) by 25.4% in the third quarter, according to the company in its most recent disclosure with the Securities and
Oluyemi Okupe Sells 23,090 Shares of Hims & Hers Health (NYSE:HIMS) Stock
04:44am, Thursday, 25'th Dec 2025
Hims and Hers Health, Inc. (NYSE: HIMS - Get Free Report) CFO Oluyemi Okupe sold 23,090 shares of Hims and Hers Health stock in a transaction on Monday, December 22nd. The shares were sold at an avera
HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling?
01:26pm, Wednesday, 24'th Dec 2025
Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Let's dive in.
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run
03:11pm, Tuesday, 23'rd Dec 2025
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
Hims & Hers Expands Subscription-Led Care as Platform Engagement Grows
12:46pm, Tuesday, 23'rd Dec 2025
HIMS deepens its subscription-led model with new care verticals, diagnostics and global expansion to boost retention.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 23'rd Dec 2025
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
